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Despitetherecentadvancesinthemanagementofcervicalcancerusingcisplatin-basedconcurrentchemoradiotherapy,substantial
treatment failure still occurs, especially in advanced-stage patients and early-stage cervical cancer patients with high-risk
prognostic factors. Therefore, eﬀorts to further improve the survival and quality of life of these patients are necessary. Nedaplatin
(cis-diammine-glycoplatinum), a derivative of cisplatin, was developed with the aim of producing a treatment with a similar
eﬀectiveness to cisplatin but decreased renal and gastrointestinal toxicities. Based on the promising results of preclinical studies,
the clinical eﬃcacy of nedaplatin as a radiosensitizing agent was evaluated in patients with cervical cancer. Retrospective analysis
of nedaplatin-based concurrent chemoradiotherapy (CCRT) against cervical cancer suggested that nedaplatin-based CCRT can be
consideredasanalternativetocisplatin-basedCCRTinbothearly-stageandadvanced-stagecervicalcancerpatients.However,due
to the lack of a randomized controlled study, nedaplatin-based CCRT has not been convincingly proven to be clinically eﬀective in
patients with cervical cancer. Further investigations in randomized controlled trials are therefore needed.
1.Introduction
Nedaplatin (cis-diammine-glycoplatinum), a derivative of
cisplatin, was developed in 1983 by Shionogi Pharmaceutical
Company in Japan with the aim of producing a treatment
with a similar eﬀectiveness to cisplatin but decreased renal
and gastrointestinal toxicities [1]. As shown in Figure 1,
nedaplatin has a novel chemical structure involving a ﬁve-
membered ring structure in which glycolate is bound to the
platinum ion as a bidentate ligand.
In a preclinical evaluation of cervical cancer, nedaplatin
demonstrated similar antitumor activity to cisplatin [2, 3].
Its lower incidence of nephrotoxicity in comparison to
cisplatin has been demonstrated to be associated with diﬀer-
encesinthekidneydistributionofthesedrugs.Whenthetwo
agents were administered at the same dose, the accumulation
of nedaplatin in the rat kidney was approximately 40% of
that of cisplatin, which explains why nedaplatin is associated
with less nephrotoxicity than cisplatin [4, 5].
Clinically, previous phase II studies conducted in Japan
suggested that nedaplatin has a particularly favorable clinical
eﬃcacy towards squamous cell carcinoma (SCC) of the
lung, head and neck, esophagus, and uterine cervix [6–
9]. According to a clinical study of nedaplatin in nonsmall
cell lung cancer patients, the response rate in patients with
SCC histology was 57.1%, which is signiﬁcantly higher than
5.5% observed in patients with nonSCC histology [9]. In the
area of uterine cervical cancer, in a phase II clinical trial,
nedaplatin demonstrated a response rate of 46% in patients
with recurrent cervical cancer, which was slightly superior
to that obtained with cisplatin (39%) [8]. Moreover, since
nedaplatin does not require hydration, nedaplatin treatment
can be managed in an outpatient setting. On the basis of
theseadvantages,nedaplatinhasbeenusedclinicallyinJapan
as an alternative to cisplatin for patients with recurrent
cervical cancer [10].
The radiosensitizing properties of nedaplatin have been
demonstrated in several preclinical studies [11, 12]. An in2 Chemotherapy Research and Practice
vitro investigation demonstrated that nedaplatin in combi-
nation with irradiation is highly eﬀective for cervical cancer
[12]. Although the preliminary data from clinical studies of
the use of nedaplatin-based CCRT in patients with head and
neck or esophageal cancer has been reported [13], however,
the clinical experience with this agent in the setting of
CCRT for cervical cancer patients is limited. As shown in
Table 1, the use of concurrent weekly nedaplatin in patients
with invasive cervical cancer in the setting of deﬁnitive
radiotherapy was investigated in two Phase I [14, 15], two
Phase II [16, 17] studies, and one retrospective study [18];
however, in the setting of adjuvant radiotherapy, nedaplatin-
based CCRT has only been evaluated in one Phase I [19]a n d
two retrospective studies [20, 21]. Thus, it remains unclear
whether nedaplatin-based CCRT is superior to RT alone in
patients with cervical cancer.
Concurrent chemoradiotherapy, usually involving 40
mg/m2 of weekly cisplatin, is accepted as the standard ﬁrst-
line treatment for cervical cancer [32, 33]. However, its
nephrotoxicity and gastrointestinal toxicity may limit its use.
In a previous Japanese Phase I study, which determined
the recommended dose of weekly cisplatin in the setting
of CCRT after radical hysterectomy, dose-limiting toxicity
(DLT) was observed at 40mg/m2, indicating that a weekly
dose of 40mg/m2 of cisplatin may be too high for Japanese
patients with cervical cancer [34]. As nedaplatin exhibits
minimal nephrotoxicity, it can be used in patients with
marginal renal function [4, 5]. Moreover, since nedaplatin
does not require hydration and shows minimal gastroin-
testinal toxicity, nedaplatin treatment can be managed in
an outpatient setting. Thus, the substitution of nedaplatin
for cisplatin as a concurrent chemotherapy for patients with
cervical cancer may be beneﬁcial.
Recently, we investigated the eﬃcacy of nedaplatin-
based CCRT in the settings of adjuvant treatment after
radical hysterectomy [18] and deﬁnitive radiotherapy [20].
Although they were retrospective in nature, to the best of our
knowledge,thesearetheonlyreportsthathavedemonstrated
a signiﬁcant improvement in the survival of cervical cancer
patients treated with nedaplatin-based CCRT. In this review,
we show the results of these retrospective analyses and
provide information on the results of other clinical studies
that investigated the eﬃcacy of nedaplatin-based CCRT in
patients with cervical cancer.
2. Postoperative Concurrent
Nedaplatin-Based Chemoradiotherapy in
Patients with Early-Stage CervicalCancer
2.1.Background. Early-stagecervicalcancerhastraditionally
been treated with either radical hysterectomy or primary
radiotherapy, with similar survival outcomes [35]. Several
risk factors have been identiﬁed that compromised the
treatment outcome in patients with Early-stage cervical
cancer who were primarily treated with radical surgery
[36–38]. Generally, patients that demonstrate risk factors
such as positive pelvic nodes, parametrial invasion, and
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Figure 1: Chemical structure of nedaplatin.
a positive vaginal margin are regarded as “high-risk” for
recurrence [36]. Moreover, patients with a tumor conﬁned
to the cervix that display risk factors such as a large tumor,
lymph vascular space invasion, and deep stromal invasion
are considered to be at “intermediate-risk” of recurrence [37,
38]. Postoperative RT is usually recommended for patients
that display these risk factors.
A previous Gynecologic Oncology Group Phase III study
(GOG 92) evaluated the role of adjuvant RT in patients that
showed “intermediate-risk” prognostic factors, that is, those
with at least two of the following risk factors after radical
hysterectomy: >1/3 stromal invasion, lymph vascular space
involvement, or a large tumor diameter. Although overall
survival was not signiﬁcantly prolonged by the addition
of adjuvant RT, this study demonstrated that adjuvant RT
signiﬁcantly reduced the risk of recurrence and prolonged
progression-free survival in these women [39, 40]. However,
the clinical beneﬁt of postoperative CCRT in patients with
Early-stage cervical cancer that displayed intermediate-risk
prognostic factors has never been investigated in the setting
of randomized clinical trials.
In early-stage cervical cancer patients demonstrating
high-risk prognostic factors, a prospective randomized clin-
ical trial (GOG 109/SWOG 87-97) examined the role of
adjuvant cisplatin-based CCRT after radical hysterectomy
and pelvic lymphadenectomy [41]. The study demonstrated
that the addition of concurrent cisplatin-based chemother-
apy to postoperative RT improved the survival of patients
with positive pelvic LN and/or a positive resection margin
and/or parametrial involvement.
Thus, it remains unclear whether postoperative
nedaplatin-based CCRT is superior to RT alone in patients
with Early-stage cervical cancer that displayed intermediate-
or high-risk prognostic factors.
To answer this question, we retrospectively evaluated
the eﬀectiveness of nedaplatin-based CCRT in 145 Japanese
patientswithFIGOStageIA2-IIBcervicalcancerafterradical
hysterectomy and pelvic lymphadenectomy [18].
2.2. Clinical Findings. As shown in Tables 2 and 3,a m o n g
the patients enrolled in the study, 57 showed intermediate-
risk prognostic factors such as deep stromal invasion,
capillary lymphatic space involvement, or a large tumor
diameter. Sixty-eight patients displayed high-risk prognostic
factors such as positive pelvic lymph nodes, parametrial
involvement, or a positive surgical margin. These patients
were postoperatively treated with either CCRT or RT alone.Chemotherapy Research and Practice 3
Table 1: Summery of the literature on nedaplatin-based concurrent chemoradiotherapy.
Author (Reference) Year Study type Setting Stage Results
J. Kodama [19] 2008 Phase I Postoperative RT Ib-IIb Weekly 35 mg/m2 of nedaplatin was
recommended.
Y. Kobayashi [21] 2009 Retro Postoperative RT Ib2-IIb
Biweekly 70mg/m2 of nedaplatin was
employed. CCRT was better than RT
alone, but the improvement was not
signiﬁcant.
S. Mabuchi [20] 2009 Retro Postoperative RT IA2-IIb
Weekly 40 mg/m2 of nedaplatin was
employed.
CCRT was signiﬁcantly better than RT
alone.
Y. Onishi [14] 2002 Phase I Deﬁnitive RT III-IVa Weekly 30 mg/m2 of nedaplatin was
recommended.
K. Yoshinaga [15] 2007 Phase I Deﬁnitive RT Ib2-IIIb Weekly 35 mg/m2 of nedaplatin was
recommended.
Y. Yokoyama [16] 2008 Phase II Deﬁnitive RT Ib2-IVa Weekly 30 mg/m2 of nedaplatin was
employed.
Y. Niibe [17] 2008 Phase II Deﬁnitive RT IIIa-IVa Weekly 30 mg/m2 of nedaplatin was
employed.
S. Mabuchi [18] 2010 Retro Deﬁnitive RT IIIb
Weekly 35mg/m2 of nedaplatin was
employed.
CCRT was signiﬁcantly better than RT
alone.
CCRT: concurrent chemoradiotherapy, Retro: retrospective cohort study, RT: radiotherapy.
Table 2: Patient characteristics and treatment outcomes (Intermediate-risk patients).
RT-group CCRT-group P-value
Patient characteristics
Number of patients 35 22
Age (mean) 49.8 49.6
Clinical stage
IA2 0 0
IB 25 18
IIA 10 4
IIB 0 0
Histology
Squamous cell 27 13
Adenocarcinoma 5 0
Adenosquamous 3 9
Others 0 0
Treatment outcome
Duration of radiotherapy Days 37 37 NS
Patients with recurrence (%) 12 (34.3) 1 (4.5) .01
PFS (months) Mean 29 36 .0026
OS (months) Mean 32.5 36 .0430
PFS: progression-free survival, OS: overall survival, CCRT: concurrent chemoradiotherapy, RT: radiotherapy.
The optimal dose of concurrent weekly nedaplatin has
not been well established in the setting of adjuvant therapy
because nedaplatin-based adjuvant CCRT has only been
p r o s p e c t i v e l ye v a l u a t e di no n eP h a s eIs t u d y[ 19], in which
the authors recommended 35mg/m2 nedaplatin for 5 weeks
as a standard treatment regimen (Table 1). However, since
weekly 40mg/m2 of cisplatin in combination with pelvic
radiotherapy has been established as a standard treatment
for cervical cancer, moreover, since the antitumor activity of
nedaplatin has been reported to be similar to that of cisplatin
[2, 3, 8], we have employed 40mg/m2 of weekly nedaplatin
for 5 weeks as a standard regimen for adjuvant CCRT in our
clinical practice.
Overall, nedaplatin-based CCRT was well tolerated.
There were no treatment-related deaths, and all patients
completed the planned pelvic RT. As shown in Table 4,
among a total of 56 patients treated with CCRT, grade 3
or 4 acute toxicities were observed in 36 patients (64.3%).
Of these, thirty patients had neutropenia alone and three
hadbothneutropeniaandthrombocytopenia.Threepatients
developed nonhematologic toxicities (bowel obstruction in
one patient, diarrhea in one patient, radiation dermatitis4 Chemotherapy Research and Practice
Table 3: Patient characteristics and treatment outcomes (High-risk patients).
RT-group CCRT-group P-value
Patient characteristics
Number of patients 34 34
Age (mean) 51.3 50.1
Clinical stage
IA2 0 0
IB 7 12
IIA 9 2
IIB 18 20
Histology
Squamous cell 21 25
Adenocarcinoma 13 8
Adenosquamous 0 1
Others 0 0
Treatment outcome
Duration of radiotherapy Days 38 38 NS
Patients with recurrence (%) 16 (47.0) 9 (26.5) NS
PFS (months) Mean 22.6 29.5 NS
OS (months) Mean 29.7 34.2 .0364
PFS: progression-free survival, OS: overall survival, CCRT: concurrent chemoradiotherapy, RT: radiotherapy.
Table 4: Grade 3-4 toxicities (acute and late toxicities).
CCRT-group RT-group
(n = 56) (n = 69)
Acute
Number of patients with Grade 3-4 acute
toxicity (%)
36 (64.3) 8 (11.6)
Hematologic
Neutropenia 30 4
Thrombocytopenia 3 0
Neutropenia + Thrombocytopenia 3 1
Nonhematologic
Bowel obstruction 1 1
Diarrhea 1 2
Dermatitis 1 0
Late
Number of patients with Grade 3-4 late
toxicity (%)
01 ( 1 . 8 )
Vesicovaginal ﬁstula 0 1
RT: radiotherapy, CCRT: concurrent chemoradiotherapy.
Table 5: Patient characteristics and treatment outcomes.
RT-group CCRT-group P-value
Patient characteristics
Number of patients 21 20
Median age 67 59
Histology SCC 21 20
Others 0 0
Dose of nedaplatin administered, mg/m2 Median (range) — 35 (10−45)
Courses of nedaplatin administered Median (range) — 5 (2−5)
Treatment outcome
PFS, months Median (range) 7 (0−60) 60 (0−60) .0015
Mean 21.4 43.3
OS, months Median 29 (1−60) 60 (5−60) .0364
Mean 32.3 47
Duration of radiotherapy Median (range) 47 (41-61) 45 (40−57) NS
Patients with recurrence (%) 14 (66.7%) 7 (35%) NS
Patients with grade 3-4 acute toxicity (%) 1 (4.8%) 10 (50%) .0014
Patients with grade 3-4 late toxicity (%) 0 (0%) 2 (10%) NS
PFS: progression-free survival, OS: overall survival, SCC: squamous cell carcinoma, CCR: concurrent chemoradiotherapy, RT: radiotherapy.Chemotherapy Research and Practice 5
Table 6: Literature review: survival, treatment failure, and complications.
Author (Reference) Year Study
type
Concurrent
chemotherapy
Brachytherapy Stage Followup Overall
Survival (%)
Treatment
Failure (%)
Late toxicity
(grade 3-4) (%)
T. Teshima [22] 1993 RCT — HDR III 5 years 53 47 10
M. Hareyama [23] 2002 RCT — HDR III 5 years 69 49 7
P.
Lertsanguansinchai
[24]
2004 RCT — HDR IIIb 3 years 71 30 7
M. Morris [25] 1999 RCT Cisplatin LDR III-IVa 5 years 63 42 12
P. G. Rose [26] 1999 RCT Cisplatin LDR II-IVa 4 years 66 38 1.7
T. Toita [27] 2005 Retro Cisplatin HDR I-III 3 years 79 33 2
Y. L. Chung [28] 2005 Phase
I/II Cisplatin HDR IIb-IVa 3 years 83 19 6
S. W. Chen [29] 2006 Retro Cisplatin HDR IIb-III 4 years 74 46 14
R. Potter [30] 2006 Retro Cisplatin HDR Ib-IVa 3 years 61 44 4
P. Novetsky [31] 2007 Retro Cisplatin HDR III-IV 5 years 65 35 6
S. Mabuchi [20] 2010 Retro Nedaplatin HDR IIIb 5 years 65 35 10
RCT: randomized controlled study, Retro: retrospective study, HDR: high-dose rate brachytherapy, LDR: low-dose rate brachytherapy.
in one patient). Among a total of 69 patients treated with
RT alone, grade 3 or 4 acute toxicities were observed in 8
patients (11.6%). Of these, four patients had neutropenia
alone and one had both neutropenia and thrombocytopenia.
Three patients developed nonhematologic toxicities (bowel
obstruction in one patient, diarrhea in two patients.). When
compared, the frequency of acute grade 3-4 acute toxicities
observed in patients treated with CCRT was signiﬁcantly
higherthanthatobservedintheRT-group(P<. 001).Never-
theless, there were no signiﬁcant diﬀerences in the length of
radiotherapy among these treatment groups (Table 2 and 3).
In this study, severe late complications were only observed in
a patient treated with RT (Table 4). This woman developed
a vesicovaginal ﬁstula 4 months after the completion of RT.
No Grade 3-4 late toxicity was observed in the patients
treated with CCRT, which may indicate that the addition of
concurrent weekly nedaplatin to pelvic RT does not increase
late toxicity.
In the intermediate-risk group, when the CCRT-group
was compared with the RT-group, as shown in Table 2
and Figure 2, CCRT was signiﬁcantly superior in terms of
recurrence rate (P = .01), PFS (log-rank; P = .0026),
and OS (log-rank; P = .0435). Moreover, as shown in
Table 3 and Figure 3, in the patients that displayed high-risk
prognostic factors, the addition of concurrent nedaplatin-
based chemotherapy also resulted in an improved outcome
in terms of OS (log-rank; P = .0364).
In conclusion, our retrospective investigation demon-
strated that the concurrent use of weekly nedaplatin with
pelvic RT is safe and improves survival outcome in early-
stage cervical cancer patients that display intermediate- or
high-risk prognostic factors. Moreover, these results indicate
that nedaplatin-based adjuvant CCRT can be considered as
an alternative to cisplatin-based adjuvant CCRT.
3.ConcurrentNedaplatin-Based
Chemoradiotherapy in Patients with
FIGOStage IIIb CervicalCancer
3.1. Background. Radiotherapy is the major treatment
modality for invasive cervical cancer and has achieved signif-
icantly improved treatment outcomes; however, substantial
treatment failure still occurs, especially in advanced-stage
patients [42].
One of the major clinical limitations in the management
of advanced-stage disease is the size of the tumor. The tumor
volume in patients with advanced-stage disease is usually
large. It is generally accepted that the ability of radiotherapy
to cure locally advanced cervical cancer is limited by the size
of the tumor because the dose required to treat a large tumor
exceeds the limit of toxicity in normal tissue [43]. Therefore,
eﬀorts to maximize local control and improve survival are
necessary.
For this purpose, various clinical studies have evaluated
the survival beneﬁt of adding concurrent chemotherapy.
When added to pelvic RT, cisplatin was found to reduce the
risk of death from cervical cancer by approximately 50%
[25, 26, 44, 45]; however, its eﬀects in patients with stage
III or greater disease are far from optimal. According to a
recent review of 18 clinical trials, the absolute 5-year survival
increase was 10% (Stage IA-IIA), 7% (Stage IIb), and 3%
(Stage III-IVa) [46]. Therefore, other therapeutic approaches
must be tested in order to further improve outcomes.
An important problem in the management of patients
with advanced-stage cervical cancer is the presence of
hydronephrosis as a result of ureteral obstruction caused
by parametrial disease. It has previously been reported that
the presence of hydronephrosis is an important indicator
of a poor prognosis [47]. The precise incidence of ureteral6 Chemotherapy Research and Practice
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Figure 2: Progression-free survival (a) and overall survival (b) in intermediate-risk patients.
obstruction is unknown, but it is reported to be 55.8%
among patients with stage III-IV disease [47]. Although
weeklycisplatinduringRThasbeenreportedtobewelltoler-
ated, its nephrotoxicity may limit its use for advanced-stage
cervical cancer patients, especially in patients with impaired
renal function due to ureteral obstruction. Therefore, the use
of an agent such as nedaplatin that shows less nephrotoxicity
as a radiosensitizer may improve the outcomes of these
patients.
Based on the US National Cancer Institute (NCI) alert
in 1999 [48], we have started the clinical use of nedaplatin-
based CCRT using HDR-ICBT to determine if concurrent
nedaplatin is a suitable alternative to cisplatin in patients
with cervical cancer.
Recently, we conducted a retrospective analysis to evalu-
ate whether nedaplatin-based CCRT is safe and superior to
RT alone in Japanese patients with FIGO stage IIIb cervical
cancer [20].
3.2. Clinical Findings. As shown in Table 5,4 1w o m e nw i t h
FIGO Stage IIIb cervical cancer were treated with either
nedaplatin-based CCRT (n = 20) or RT alone (n = 21).
Among the patients treated with CCRT, the median dose
of nedaplatin administered was 35mg/m2, and the median
number of courses of nedaplatin was ﬁve. The optimal dose
of concurrent weekly nedaplatin for patients with invasive
cervical cancer treated by primary CCRT using EBRT
and HDR-ICBT is still unknown, but has previously been
investigatedinseveralprospectiveclinicalstudies[14–17].Of
these, three studies recommended 30mg/m2, and the other
recommended 35mg/m2 nedaplatin as a standard treatment
regimen (Table 1). Therefore, the dose of nedaplatin utilized
in our study was consistent with these previous studies.
Overall, nedaplatin-based CCRT was well tolerated. All
patients completed the planned EBRT and HDR-ICBT.
As shown in Table 5, grade 3 or 4 acute toxicities were
observed in 10 patients (50%) in the CCRT-group. The
most frequently observed acute toxicity was neutropenia
or a combination of neutropenia and thrombocytopenia.
The overall incidence of grade 3-4 acute toxicities was
signiﬁcantly higher in the CCRT-group than in the RT-
group. However, there were no signiﬁcant diﬀerences in
the duration of radiotherapy among these treatment groups
(Table 5).
With regard to radiotherapy using EBRT and LDR-ICBT,
late toxicity from concurrent chemotherapy has been exam-
ined previously (Table 6), and no diﬀerences were found in
the rates of bowel or bladder toxicity between the patients
treated with RT alone and those treated with CCRT [49].
However, because of the lack of a controlled clinical study, it
is not clear whether concurrent chemotherapy increases the
incidence of late toxicity in the setting of radiotherapy using
EBRTandHDR-ICBT.Inourstudy,severelatecomplications
were observed in two patients (10%) treated with CCRT.
As shown in Table 5, the rate of severe late complications
in the CCRT-group (10%) was similar to those of other
series in which the patients had been treated with EBRT and
HDR-ICBT without concurrent chemoradiotherapy [22–
24], cisplatin-based CCRT using EBRT and LDR-ICBT [25,
26], or cisplatin-based CCRT using EBRT and HDR-ICBT
[27–31]. Collectively, these results (including ours) suggest
that the addition of concurrent weekly nedaplatin to EBRT
and HDR-ICBT does not increase late toxicity.
When the CCRT-group was compared with the RT-
group, as shown in Figure 4 and Table 5, CCRT was found
to be signiﬁcantly superior in terms of PFS (log-rank; P =
.0015) and OS (log-rank; P = .0364), and the risk of
death was decreased by 46% by the addition of nedaplatin-
based concurrent chemotherapy. These results indicate that
the addition of concurrent nedaplatin to pelvic EBRT plusChemotherapy Research and Practice 7
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Figure 3: Progression-free survival (a) and overall survival (b) in high-risk patients.
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Figure 4: Progression-free survival (a) and overall survival (b) among patients in the CCRT- and RT-groups.
HDR-ICBT signiﬁcantly improved the prognosis of this
patient population. The 5-year overall survival rate of 65%
and the treatment failure rate of 35% found in our study
are comparable to those demonstrated in previous clinical
studies of cisplatin-based CCRT (Table 6). These results
suggest that in this patient population nedaplatin can be
considered as an alternative to cisplatin in the setting of
chemoradiotherapy.
3.3. Future Directions and Prospects. Although the addition
of concurrent nedaplatin-based chemotherapy to pelvic RT
resulted in improved survival in our studies, a signiﬁcant
number of cervical cancer patients still suﬀered recurrence
and died of their disease. Therefore, to further improve the
prognosis of these patients, novel treatment strategies such
as the use of nedaplatin-based combination chemotherapy
as a radiosensitizer, the coadministration of nedaplatin
with molecularly targeted agents, improved drug delivery
strategies using delivery vehicles such as liposomes, or more
conformal dose distributions with intensity-modulated RT
need to be investigated in future trials.
In contrast to cisplatin-based CCRT, due to the lack
of prospective randomized studies, nedaplatin-based CCRT
has not been convincingly proven to be clinically eﬀective
for the treatment of cervical cancer. However, given the
advantage of patient’s tolerance as well as its signiﬁcant8 Chemotherapy Research and Practice
activity demonstrated in these studies, we believe that
nedaplatin-based CCRT is a reasonable treatment option
for this patient population. To deﬁnitively demonstrate the
activity of nedaplatin-based CCRT, further investigation in
a randomized controlled trial, for example, to compare
concurrent nedaplatin versus cisplatin in the setting of
CCRT, is warranted.
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